AIM To compare the effects of liposomes andglyco-poly-L-lysine on liver targeted uptake andexpression of plasmid in rat liver.METHODS After binding with lipofectamine orgalactose-terminal glyco-poly-L-lysine,theplasmi...AIM To compare the effects of liposomes andglyco-poly-L-lysine on liver targeted uptake andexpression of plasmid in rat liver.METHODS After binding with lipofectamine orgalactose-terminal glyco-poly-L-lysine,theplasmid could be expressed in eukaryotic cellswhen injected into Wistar rats by intravenousroute.At different time intervals after the injection,the distribution and expression of the plasmid inliver of rats were observed and compared using insitu hybridization and immunohistochemistry.RESULTS The expression of the plasmid bindingto liposomes or G-PLL could be markedly observed24 h later,and began to decrease one week later,but it still could be observed up to three weeks.Both liposomes and G-PLL could deliver theplasmid to the liver effectively,but the effect of thelatter was better than the former concerning thedistribution and expression of the plasmid targeteduptake in the liver.CONCLUSION G-PLL is better than liposome asthe targeted carrier for delivering exogenous genesto the liver.展开更多
AIM To compare the effects of intravenous routeand peritoneal route on liver targeted uptake andexpression of plasmid delivered by galactose-terminal glyco-poly-L-lysine(G-PLL).METHODS The plasmid pTM/MMP-1 which coul...AIM To compare the effects of intravenous routeand peritoneal route on liver targeted uptake andexpression of plasmid delivered by galactose-terminal glyco-poly-L-lysine(G-PLL).METHODS The plasmid pTM/MMP-1 which couldbe expressed in eukaryotic cells was bound to G-PLL,and was then transferred into Wistar rats byintravenous and intraperitoneal injection.Theexpression and distribution of the plasmid wereobserved at different time periods by in situhybridization and immunohistochemistry.RESULTS The plasmid could be expressedsignificantly within 24 h after being transferred invivo by both intravenous and intraperitonealroutes.One week later the expression began todecrease,and could still be observed three weekslater.Although both the intravenous andintraperitoneal route could target-specificallydeliver the plasmid to the liver,the effect of theformer was better as compared to that of the latter.CONCLUSION Intravenous route is better for livertargeted uptake and expression of G-PLL-boundplasmids than the peritoneal route.展开更多
This work investigated the effect of glyco-regioisomerism of glycopolymers on their dynamic interaction with benzoxaborole-containing polymers. Two kinds of glycopolymers, P-1-Gal and P-6-Gal, i.e. galactoside pendant...This work investigated the effect of glyco-regioisomerism of glycopolymers on their dynamic interaction with benzoxaborole-containing polymers. Two kinds of glycopolymers, P-1-Gal and P-6-Gal, i.e. galactoside pendant group linked to the identical main chain through its anomeric(C1) and C6-hydroxyl group position, respectively, were studied. We found that P-6-Gal showed stronger binding strength to the PNIPAM-co-PBOB polymer than P-1-Gal did, which controlled the macroscopic property of the resultant hydrogels at a molecular level.展开更多
A series of novel glyco-gambogic acid（GA） compounds were synthesized and evaluated for their in vitro anti-proliferative activity against human hepatocellular carcinoma（HCC） cells.All compounds showed much better ...A series of novel glyco-gambogic acid（GA） compounds were synthesized and evaluated for their in vitro anti-proliferative activity against human hepatocellular carcinoma（HCC） cells.All compounds showed much better aqueous solubility（0.92- 1.89 mg/mL） than GA（0.013 mg/mL）,and displayed potent inhibition on HCC cells（IC_（50）：0.21-12.23μmol/L） and little affects on non-tumor liver cells（IC_（50）：42.56-86.43μmol/L）,suggesting that glyco-GA compounds selectively inhibit HCC proliferation,and may be promising candidates for further intensive study.展开更多
目的研究扶正化瘀肝糖综合治疗方案治疗乙型肝炎后肝硬化合并糖代谢异常的临床疗效。方法采用随机对照临床试验,将乙型肝炎后肝硬化合并糖代谢异常的患者随机分为治疗组(68例)和对照组(74例),分别采用扶正化瘀肝糖综合治疗方案和中西医...目的研究扶正化瘀肝糖综合治疗方案治疗乙型肝炎后肝硬化合并糖代谢异常的临床疗效。方法采用随机对照临床试验,将乙型肝炎后肝硬化合并糖代谢异常的患者随机分为治疗组(68例)和对照组(74例),分别采用扶正化瘀肝糖综合治疗方案和中西医常规综合治疗方案治疗3个月,检测两组治疗前后空腹血糖(FPG)、糖负荷后2 h血糖(2 h PG)及空腹胰岛素(FINS)等指标,计算胰岛素抵抗指数(HOMA- IR),并记录治疗前后证候评分情况,通过统计分析,分别评定其中医证候疗效和糖代谢异常疗效。结果治疗后两组2 h PG较治疗前均显著下降(P<0.01),治疗组治疗前后FPG差值及HOMA-IR差值与对照组比较差异有统计学意义(P<0.05),治疗组中医证候好转率(85.3%)和糖代谢异常的总有效率(80.9%)均明显优于对照组(64.9%,62.2%),差异有统计学意义(P<0.01,P<0.05)。结论扶正化瘀肝糖综合治疗方案具有改善乙型肝炎后肝硬化合并糖代谢异常患者中医证候和糖代谢异常的疗效。展开更多
基金the National Natural Science Foundation of China(№39570336).
文摘AIM To compare the effects of liposomes andglyco-poly-L-lysine on liver targeted uptake andexpression of plasmid in rat liver.METHODS After binding with lipofectamine orgalactose-terminal glyco-poly-L-lysine,theplasmid could be expressed in eukaryotic cellswhen injected into Wistar rats by intravenousroute.At different time intervals after the injection,the distribution and expression of the plasmid inliver of rats were observed and compared using insitu hybridization and immunohistochemistry.RESULTS The expression of the plasmid bindingto liposomes or G-PLL could be markedly observed24 h later,and began to decrease one week later,but it still could be observed up to three weeks.Both liposomes and G-PLL could deliver theplasmid to the liver effectively,but the effect of thelatter was better than the former concerning thedistribution and expression of the plasmid targeteduptake in the liver.CONCLUSION G-PLL is better than liposome asthe targeted carrier for delivering exogenous genesto the liver.
基金National Natural Science Foundation of China(№39570336).
文摘AIM To compare the effects of intravenous routeand peritoneal route on liver targeted uptake andexpression of plasmid delivered by galactose-terminal glyco-poly-L-lysine(G-PLL).METHODS The plasmid pTM/MMP-1 which couldbe expressed in eukaryotic cells was bound to G-PLL,and was then transferred into Wistar rats byintravenous and intraperitoneal injection.Theexpression and distribution of the plasmid wereobserved at different time periods by in situhybridization and immunohistochemistry.RESULTS The plasmid could be expressedsignificantly within 24 h after being transferred invivo by both intravenous and intraperitonealroutes.One week later the expression began todecrease,and could still be observed three weekslater.Although both the intravenous andintraperitoneal route could target-specificallydeliver the plasmid to the liver,the effect of theformer was better as compared to that of the latter.CONCLUSION Intravenous route is better for livertargeted uptake and expression of G-PLL-boundplasmids than the peritoneal route.
基金supported by the National Natural Science Foundation of China (21604042, 21504016, 91527305)the Natural Science Foundation of Jiangsu Province of China (BK20150843)NUPTSF (NY215017, NY215080)
文摘This work investigated the effect of glyco-regioisomerism of glycopolymers on their dynamic interaction with benzoxaborole-containing polymers. Two kinds of glycopolymers, P-1-Gal and P-6-Gal, i.e. galactoside pendant group linked to the identical main chain through its anomeric(C1) and C6-hydroxyl group position, respectively, were studied. We found that P-6-Gal showed stronger binding strength to the PNIPAM-co-PBOB polymer than P-1-Gal did, which controlled the macroscopic property of the resultant hydrogels at a molecular level.
基金supported by a grant from the Nature and Science Foundation of Department of Education,Anhui province(No.KJ2010A204)
文摘A series of novel glyco-gambogic acid（GA） compounds were synthesized and evaluated for their in vitro anti-proliferative activity against human hepatocellular carcinoma（HCC） cells.All compounds showed much better aqueous solubility（0.92- 1.89 mg/mL） than GA（0.013 mg/mL）,and displayed potent inhibition on HCC cells（IC_（50）：0.21-12.23μmol/L） and little affects on non-tumor liver cells（IC_（50）：42.56-86.43μmol/L）,suggesting that glyco-GA compounds selectively inhibit HCC proliferation,and may be promising candidates for further intensive study.
文摘目的研究扶正化瘀肝糖综合治疗方案治疗乙型肝炎后肝硬化合并糖代谢异常的临床疗效。方法采用随机对照临床试验,将乙型肝炎后肝硬化合并糖代谢异常的患者随机分为治疗组(68例)和对照组(74例),分别采用扶正化瘀肝糖综合治疗方案和中西医常规综合治疗方案治疗3个月,检测两组治疗前后空腹血糖(FPG)、糖负荷后2 h血糖(2 h PG)及空腹胰岛素(FINS)等指标,计算胰岛素抵抗指数(HOMA- IR),并记录治疗前后证候评分情况,通过统计分析,分别评定其中医证候疗效和糖代谢异常疗效。结果治疗后两组2 h PG较治疗前均显著下降(P<0.01),治疗组治疗前后FPG差值及HOMA-IR差值与对照组比较差异有统计学意义(P<0.05),治疗组中医证候好转率(85.3%)和糖代谢异常的总有效率(80.9%)均明显优于对照组(64.9%,62.2%),差异有统计学意义(P<0.01,P<0.05)。结论扶正化瘀肝糖综合治疗方案具有改善乙型肝炎后肝硬化合并糖代谢异常患者中医证候和糖代谢异常的疗效。
